24/7 Market News Snapshot 16 July, 2025 – Aptorum Group Limited Class A Ordinary Shares (NASDAQ:APM)
DENVER, Colo., 16 July, 2025 (www.247marketnews.com) – (NASDAQ:APM) are discussed in this article.
Aptorum Group Limited has captured significant attention in the financial markets, witnessing a dramatic increase in its Class A Ordinary Shares, which surged 80.24% to $1.748 in pre-market trading, up from $0.970 at the previous close. This remarkable rise was accompanied by a trading volume of 5.47 million shares, signaling strong investor confidence and sentiment towards the company. Analysts suggest that if this bullish trend persists, further gains could be on the horizon as key resistance levels are approached.
In a strategic move to bolster its clinical capabilities, Aptorum has recently announced a definitive agreement to merge with DiamiR Biosciences, a forward-thinking developer of innovative blood tests targeting brain health. The merger, structured as an all-stock transaction, will integrate DiamiR as a wholly-owned subsidiary, allowing it to maintain its brand identity while enhancing Aptorum’s portfolio.
Ian Huen, CEO and Chairman of Aptorum, expressed his enthusiasm for the merger, underscoring the value it aims to create for shareholders. He noted that the collaboration with DiamiR is poised to deliver both immediate and long-term advantages, particularly by leveraging DiamiR’s blood-based diagnostic platform, which addresses critical health concerns, including aging-related conditions.
DiamiR’s CEO, Dr. Alidad Mireskandari, lauded the merger as a strategic alignment set to propel both entities forward in their pursuit of advanced clinical and pharmaceutical services. The anticipated closing of the merger, scheduled for the fourth quarter of 2025, is subject to stockholder approval and other customary conditions. Upon consummation, approximately 70% of the combined company’s equity will be retained by DiamiR shareholders, ensuring strong alignment toward future growth.
Executive leadership after the merger will include Ian Huen as CEO, Dr. Mireskandari as President and COO, and Gary Anthony as CFO, all contributing to the shared vision of enhancing healthcare through innovative therapeutics and diagnostics in the biopharmaceutical landscape.